Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically engineered superantigens as tolerable antitumor agents

J Hansson1, L Ohlsson, R Persson

  • 1Lund Research Center, Pharmacia & Upjohn, Sweden.

Proceedings of the National Academy of Sciences of the United States of America
|March 18, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"It's ok that I feel like this": a qualitative study of adolescents' and parents' experiences of facilitators, mechanisms of change and outcomes in a joint emotion regulation group skills training.

BMC psychiatry·2023
Same author

Splitting phonons: Building a platform for linear mechanical quantum computing.

Science (New York, N.Y.)·2023
Same author

The epidemiology of upper respiratory tract disorders in a population of insured Swedish dogs (2011-2014), and its association to brachycephaly.

Scientific reports·2023
Same author

Correction to: Beyond the Economic Gaze: Childbearing During and After Recessions in the Nordic Countries.

European journal of population = Revue europeenne de demographie·2021
Same author

Anti-apoptotic effect of adipose tissue-derived stromal vascular fraction in denervated rat muscle.

Stem cell research & therapy·2021
Same author

Beyond the Economic Gaze: Childbearing During and After Recessions in the Nordic Countries.

European journal of population = Revue europeenne de demographie·2020

Engineered superantigens (SAg) targeting tumors show potent T cell activation for cancer therapy. A mutated fusion protein significantly reduced toxicity while maintaining strong antitumor effects in preclinical models.

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Superantigens (SAg) are potent immune activators binding to MHC class II molecules.
  • SAg can activate a high frequency of T cells, making them promising for immunotherapy.
  • Current SAg therapies face challenges due to systemic toxicity.

Purpose of the Study:

  • To develop a tumor-targeted superantigen fusion protein for enhanced cancer therapy.
  • To reduce the systemic toxicity associated with superantigen-based treatments.
  • To evaluate the efficacy and safety of a mutated superantigen immunoconjugate.

Main Methods:

  • Engineered a fusion protein combining a tumor-reactive antibody fragment (C215Fab) with staphylococcal enterotoxin A (SEA).
  • Introduced a D227A point mutation in SEA to ablate MHC class II binding and reduce toxicity.

Related Experiment Videos

  • Treated tumor-bearing mice with the engineered Fab-SEA D227A fusion protein and assessed antitumor effects and toxicity.

    • Main Results:

    • The Fab-SEA D227A fusion protein demonstrated significant antitumor activity in mice.
    • Treatment with the mutated SAg fusion protein resulted in markedly reduced toxicity compared to wild-type.
    • Reduced toxicity correlated with limited distribution in MHC class II-rich tissues and lower systemic cytokine levels.

    Conclusions:

    • Engineered immunoconjugates with mutated superantigens offer a promising strategy for T cell-mediated tumor therapy.
    • The D227A mutation effectively mitigates superantigen systemic toxicity while preserving antitumor efficacy.
    • This approach enables targeted T cell activation against tumors with minimal systemic immune side effects.